Patents by Inventor Richard Axel
Richard Axel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020076759Abstract: This invention provides an isolated nucleic acid molecule encoding a vertebrate pheromone receptor. This invention also provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of the nucleic acid molecule which encodes a pheromone receptor. This invention provides a vector which comprises the above-described isolated nucleic acid molecule. This invention also provides a purified, vertebrate pheromone receptor. This invention provides an antibody capable of specifically binding to a vertebrate pheromone receptor. The invention further methods for identifying ligands capable of affecting the activity of a pheromone receptor. This invention provides different uses of the identified ligands. This invention also provides a transgenic nonhuman living organism expressing a pheromone receptor.Type: ApplicationFiled: July 3, 2001Publication date: June 20, 2002Inventors: Catherine Dulac, Richard Axel
-
Publication number: 20020064817Abstract: The invention provides an isolated nucleic acid molecule encoding an odorant receptor. The invention also provides expression vectors containing such nucleic acid, purified odorant receptor proteins encoded by the nucleic acid, and transfected cells expressing the receptor proteins. The invention further provides methods of identifying odorant ligands and odorant receptors, of developing fragrances, of identifying appetite suppressant compounds, of controlling appetite, of controlling pest populations, of promoting and inhibiting fertility, and of detecting odors.Type: ApplicationFiled: January 26, 2001Publication date: May 30, 2002Inventors: Linda B. Buck, Richard Axel
-
Patent number: 6093539Abstract: This invention provides an isolated single-stranded nucleic acid which encodes an aqueous-soluble polypeptide comprising at least a portion of a human T4 glycoprotein, which portion specifically forms a complex with a human immunodeficiency virus envelope glycoprotein.Type: GrantFiled: June 6, 1995Date of Patent: July 25, 2000Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss, J. Steven McDougal
-
Patent number: 5958678Abstract: A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4.sup.+ cells.Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: December 12, 1994Date of Patent: September 28, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss, J. Steven McDougal
-
Patent number: 5871913Abstract: A single-stranded nucleic acid molecule which encodes the amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4 cells. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss, J. Steven McDougal
-
Patent number: 5422274Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.Type: GrantFiled: February 5, 1992Date of Patent: June 6, 1995Assignees: The Trustees of Columbia University in the City of New York, SmithKline Beckman CorporationInventors: Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
-
Patent number: 5179017Abstract: The present invention relates to processes for inserting DNA into eucaryotic cells, particularly DNA which includes a gene or genes coding for desired proteinaceous materials for which no selective criteria exist. The insertion of such DNA molecules is accomplished by cotransforming eucaryotic cells with such DNA together with a second DNA which corresponds to a gene coding for a selectable marker.This invention also concerns processes for producing proteinaceous materials such as insulin, interferon protein, growth hormone and the like which involve cotransforming eucaryotic cells with DNA which codes for these proteinaceous materials, growing the cotransformed cells for production of the proteinaceous material and recovering the proteinaceous material so produced.The invention further relates to processes for inserting into eucaryotic cells a multiplicity of DNA molecules which includes genes coding for desired proteinaceous materials.Type: GrantFiled: June 18, 1991Date of Patent: January 12, 1993Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Axel, Michael H. Wigler, Saul J. Silverstein
-
Patent number: 5149636Abstract: Multiple copies of a foreign DNA I coding for the production of a protein may be introduced into eucaryotic cells by cotransforming suitable cells with foreign DNA I and with foreign DNA II which includes a functionally deficient, amplifiable gene coding for a selectable or identifiable trait, preferably carried on the same DNA molecule as a foreign DNA III, which includes a functional, amplifiable gene coding for another selectable or identifiable trait. The cotransformation is carried out under suitable conditions permitting selection or identification of cells expressing the gene on DNA I or that on DNA III, but not that on DNA II. The cotransformed cells so identified or selected are recovered and cloned under conditions where the functionally deficient gene on DNA II is expressed. Cells expressing the gene on DNA II are recovered. They contain multiple copies of DNA I. This method can be used to produce mRNA transcripts or protein products such as human and animal growth hormone, insulin and the like.Type: GrantFiled: September 26, 1988Date of Patent: September 22, 1992Assignee: Trustees of Columbia University in the City of New YorkInventors: Richard Axel, James M. Roberts
-
Patent number: 5126433Abstract: A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: October 23, 1987Date of Patent: June 30, 1992Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Leonard Chess, Richard Axel, Robin Weiss, Dan R. Littman, J. Steven McDougal
-
Patent number: 5110906Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.Type: GrantFiled: February 24, 1988Date of Patent: May 5, 1992Assignees: The Trustees of Columbia University in the City of New York, Smithkline Beckman CorporationInventors: Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
-
Patent number: 4985352Abstract: The invention relates to DNA encoding a functional serotonin 5HT1c receptor, e.g., cDNA, and to the isolated, functional serotonin 5HT1c receptor encoded by such DNA. The invention also relates to mammalian cells expressing the cDNA encoding the 5HT1c receptor and to a DNA probe useful for detecting nucleic acid encoding the serotonin 5HT1c receptor. This invention provides methods for determining binding to the serotonin 5HT1c receptor, methods of detecting the expression, and the presence of the serotonin 5HT1c receptor on the surface of a cell and to a method of screening drugs to identify drugs which specifically interact with, and bind to the serotonin 5HT1c receptor on the surface of a cell.Type: GrantFiled: January 18, 1989Date of Patent: January 15, 1991Assignee: The Trustees of Columbia University in the City of New YorkInventors: David J. Julius, Richard Axel, Thomas M. Jessell
-
Patent number: 4839293Abstract: DNA which encodes the polypeptide streptavidin has been isolated as a fragment 2 kb in length derived from a restriction endonuclease digestion of the chromosomal DNA of Streptomyces avidinii. The nucleic acid sequence of the gene and the amino acid sequence of the polypeptide have been determined. A fused gene has been prepared which comprises the streptavidin gene fused to a gene encoding the human LDL receptor. Expression of the gene fusion results in a fused streptavidin-human LDL receptor polypeptide. Methods are provided for using the fused gene to produce labeled, chemically modified proteins in vivo and to isolate a protein knowing only the nucleotide sequence of the gene encoding the protein.Type: GrantFiled: February 24, 1986Date of Patent: June 13, 1989Assignee: The Trustees of Columbia University in the City of New YorkInventors: Charles R. Cantor, Richard Axel, Carlos Argarana
-
Patent number: 4634665Abstract: The present invention relates to processes for inserting DNA into eucaryotic cells, particularly DNA which includes a gene or genes coding for desired proteinaceous materials for which no selective criteria exist. The insertion of such DNA molecules is accomplished by cotransforming eucaryotic cells with such DNA together with a second DNA which corresponds to a gene coding for a selectable marker.This invention also concerns processes for producing proteinaceous materials such as insulin, interferon protein, growth hormone and the like which involve cotransforming eucaryotic cells with DNA which codes for these proteinaceous materials, growing the contransformed cells for production of the proteinaceous material and recovering the proteinaceous material so produced.The invention further relates to processes for inserting into eucaryotic cells a multiplicity of DNA molecules which includes genes coding for desired proteinaceous materials.Type: GrantFiled: August 11, 1983Date of Patent: January 6, 1987Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Axel, Michael H. Wigler, Saul J. Silverstein
-
Patent number: 4399216Abstract: The present invention relates to processes for inserting DNA into eucaryotic cells, particularly DNA which includes a gene or genes coding for desired proteinaceous materials for which no selective criteria exist. The insertion of such DNA molecules is accomplished by cotransforming eucaryotic cells with such DNA together with a second DNA which corresponds to a gene coding for a selectable marker.The invention further relates to processes for inserting into eucaryotic cells a multiplicity of DNA molecules including genes coding for desired proteinaceous materials by cotransformation with the desired genes and with amplifiable genes for a dominant selectable marker in the presence of successively higher amounts of an inhibitor.Type: GrantFiled: February 25, 1980Date of Patent: August 16, 1983Assignee: The Trustees of Columbia UniversityInventors: Richard Axel, Michael H. Wigler, Saul J. Silverstein